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The Cat and Mouse Games Minireview
That Genes, Viruses,
and Cells Play
Robert A. Weinberg (Serrano et al., 1997). They examine the consequences
of introducing a mutant ras oncogene into cells. In theWhitehead Institute for Biomedical Research
1970s, the effects elicited by a ras oncogene wereDepartment of Biology Massachusetts Institute
thought obvious: ostensibly normal cells exposed toof Technology
this gene would become transformed into cancer cells.Cambridge, Massachusetts 02142
Then, in 1983, the beginnings of subtlety became appar-
ent. When the ras oncogene was inserted into truly nor-
mal cells (rather than the already immortalized cells used
When viruses and oncogenes first moved into molecular in the 1970s), the result was quite different. These truly
view a generation ago, we felt pleased to learn about normal cells, prepared directly from embryonic tissues,
the ways inwhich they directly affected cells. Now, years resisted the effects of the inserted ras and refused to
later, we have come to realize that the interactions that become transformed. They continued to sit quietly in
viruses and oncogenes have with the cells around them the monolayer and gave no indication of carrying a ras
are much more complex, certainly much more interest- oncogene in their genome (Newbold and Overell, 1983).
ing. These days, we talk in terms of the immediateeffects The rationale of this seemingly paradoxical response
that genes and viruses have on cells, the counter- to ras was apparent, even then. Normal cells appear to
measures that cells take to resist these changes, and be hardwired to resist transformation by ras. Complex
the counter-countermeasures taken to thwart hastily metazoans like ourselves seem to require such cellular
erected cellular defense mechanisms. hardwiring to survive. The 1016 cell cycles that we experi-
These tit-for-tat games have been dramatically illus- ence in a lifetime are guaranteed to generate millions
trated by studies of the replication cycles of some vi- of cells carrying (point)mutated ras oncogenes, largely
ruses. In one well-studied model, cytomegalovirus be- consequences of inadvertant errors in DNA replication.
gins the dance by initiating its growth cycle inside a Any one of these cells might well succeed in spawning
fibroblast. This cell responds with a countermeasure: it a clone of malignant descendants, and each would need
tries to alert the immune system to its plight by dis- to be stopped in its tracks before clonal expansion
begins.playing viral antigenic peptides on its surface MHC class
This hardwired resistance to transformation by rasI molecules. The virus, intent on continuing its agenda
(and other mutant oncogenes) may represent the pri-of unimpeded multiplication, then launches its counter-
mary defense against tumorigenesis in our bodies, farcountermeasure by aborting the biosynthesis of the
more important than other countermeasures such asclass I molecules (Beersma et al., 1993).
immune surveillance of mutant cells. Still, the molecularA parallel but quite distinct dynamic operates during
nature of the cell’s resistance to transformation re-the replicative cycles of a variety of DNA viruses, among
mained obscure for almost 15 years. Serrano et al. havethem adenovirus. When an adenovirus-infected cell
now uncovered some of it.senses the virus in its midst, it tries to trigger its apop-
They show that a cell may respond to a ras oncogenetotic program; by killing itself, the cell may succeed in
by displaying a phenotype that is, by all available criteria,aborting the viral replicative cycle, thereby sparing the
indistinguishable from cellular senescence. Until re-tissue around it from further spread of virus. The virus,
cently, senescence had been conceptualized in a veryanticipating the cell’s countermeasures, then launches
different way. As Hayflick first demonstrated more thanits counter-countermeasure: needing to spare its host
30 years ago, after a large but definable number of repli-for a time long enough to produce viral progeny, thevirus
cative generations in culture, cells will stop growingdispatches proteins that neutralize the host’s apoptotic
although they will remain viable for an extended periodresponse (Debbas and White, 1993).
of time (Hayflick and Moorhead, 1961). This growth stop-Oncogenes and Cancer Cells
page and, as revealed more recently, the acquisition
The process of cell transformation now seems to follow
of other biochemical attributes (Cristofalo and Pignolo,
a similar 3-step dance. In this instance, the antagonists 1996), seemed to be triggered by a generational clock.
are the growth-regulating machinery of the cell and the The clock counted the replicative cycles through which
mutant cancer genes that occasionally arise in its ge- a cell population had passed and then triggered growth
nome. Evidence from a number of sources indicates stoppage—senescence—when it registered a pre-set
that the appearance of a mutant growth-regulating gene number of generations.
in a cell (i.e., an activated oncogene or an inactivated The term “senescence” was inspired by the notion
tumor suppressor gene) often provokes this cell to shut that these cell cultures had become aged. But Serrano
down its further proliferation. By limiting its own replica- et al. now demonstrate that even young cultures can be
tive options, the single mutant cell hopes to spare the provoked to senescewithin severaldays of experiencing
organism from the threat of cancer. But the process of the effects of an introduced ras oncogene. The term
tumorigenesis, which is always clever and often relent- “senescence” must therefore be reconceptualized. It is
less, can thwart this defense mechanism: a second mu- no longer the monopoly of old cultures and aged cells.
tant gene may arise that disables the growth shutdown Senescence now takes a place next to apoptosis; they
response of the cell. both represent short-term responses that cells may acti-
The choreography of these thrust-and-parry maneu- vate in order to block irreversibly their own further prolif-
eration.vers is laid out in the paper by Serrano et al. in this issue
Cell
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Like apoptosis, senescence can now be viewed as a here: in response to a ras oncogene, a cell may slow
down its growth and sink into a state of prolonged de-reflex that cells will activate in response to multiple stim-
uli. Apoptosis may be triggered by genomic damage, crepitude rather than lurch abruptly into total senes-
cence. After limping along for years, even decades, oneconflicting growth-regulatory signals, or death factors
such as the Fas ligand. The exhaustion of allotted repli- of its slowly proliferating descendants may succeed in
knocking out one of the tumor suppressor genes thatcative cycles or the inadvertant activation of an onco-
gene can trigger senescence. It is likely that yet other have been holding back growth. Only then can the rapid,
sustained clonal expansion associated with trans-physiologic signals will be found that are equally capa-
ble of triggering the senescence response. formed cell populations begin.
Cancer and ImmortalityCooperating Mutations
An oncogene-bearing, pre-malignant cell will need to This model also explains another longstanding puzzle
in cancer cell biology. As mentioned above, in 1983,circumvent the senescence countermeasure erected by
its own internal circuitry in order to advance its agenda researchers observed that primary cultures of embry-
onic cells resist transformation by a ras oncogene whileof progressing toward a fully malignant state. How such
a cell succeeds in subverting the senescence reponse immortalized cells are highly susceptible. On its surface,
this observation made little sense: The refractory pri-is also revealed by Serrano et al. As is often the case
these days, the mechanistic answers to questions like mary cells were still many replicative cycles away from
exhausting their allotment of generational doublings.these come from examining the components of another
clocking device—the cell cycle clock apparatus. Why should their state of immortalization (or lack
thereof) affect their short-term responsiveness to anAfter several days exposure to a ras oncogene, a cell
will begin to make high levels of p16 and p53. p16, also introduced oncogene?
The answer appears to come from an examination ofknown as p16INK4A, is a well-studied, specific inhibitor of
the CDK4 and CDK6 cyclin-dependent kinases (CDKs) precisely how cultured cells achieve replicative immor-
tality. They often do so by inactivating their p16 or p53that operate during the G1 phase of the cell cycle. These
kinases function to phosphorylate and thereby inacti- genes (Whitaker et al., 1995); one or the other gene
inactivation seems to be selected during extended pas-vate the growth-suppressing activities of pRB, the reti-
noblastoma protein, as well as the related p107 and sage in culture. As an unintended side-product of such
gene inactivations, immortalized cells also lose their pri-p130 proteins (Weinberg, 1995). The actions of p53 are
more far-reaching. Acting as a transcription factor, it mary defense mechanism against oncogene-induced
transformation. The fact that cells use senescence asinduces expression of another CDK inhibitor, p21, which
antagonizes a spectrum of CDKs operating throughout a response to two unrelated provocations (oncogene
transformation and excessive generational doublings)the cell cycle. (p53 may also mobilize other downstream
growth-inhibitory effectors, not all of which have been means that selection for one phenotype (ability to double
indefinitely) affects their responses to an unrelated stim-elucidated) (Levine, 1997).
These inductions of p16 and p53 proteins are far more ulus (oncogene activation).
Collaborating Oncogenesthan epiphenomena of senescence. They appear, in-
stead, to be causally involved in triggering this state. The above-cited work explains how an oncogene activa-
tion (ras) can cooperate with the inactivation of a tumorAs Serrano et al. demonstrate, experimental inactivation
of either encoding gene subverts the senescence re- suppressor gene (p16 or p53) to achieve cell transforma-
tion. It also provides a compelling molecular explanationsponse of the cell.
Now we realize the counter-countermeasure that as- for how two oncogenes can collaborate in cell transfor-
mation. For example, the ras oncogene is known topiring cancer cells will take to override ras-induced se-
nescence: they will inactivate through mutation either collaborate with the adenovirus E1A, SV40 large T, or
human papilloma virus E6 or E7 oncogenes to transformtheir p16 or p53 genes. Either change will do. Impor-
tantly, these gene inactivations occur frequently in spon- primary cells. (Land et al., 1983; Ruley, 1983, 1990).
Three of these (E1A, large T, and E7) are known to dis-taneously arising tumors. A substantial body of evidence
indicates that the p53 or p16 genes (or both) are mutated able pRB, the primary target of CDK4 and CDK6 phos-
phorylation. A wealth of biochemical evidence indicatesin the vast majority of human tumors. (Hollstein et al.,
1994; Hirama and Koeffler, 1995). that the disabling of pRB should result in a close pheno-
copy of p16 inactivation (Weinberg, 1995). Two of theseThese observations provide a compelling mechanistic
explanation of why cells need to mutate multiple genes oncogenes (large T and E6) antagonize p53; Serrano et
al. would argue that this is equally effective in disablingin order to become fully transformed. In this instance,
the first mutation, which activates ras, provides the cell senescence and rendering a cell susceptible to ras
transformation.with the growth impetus required for sustained prolifera-
tion. The second mutation (inactivating either p16 or In fact, ras activation and subsequent p53 inactivation
figure prominently in the best-studied example of humanp53) has no direct effect on cell proliferation per se.
Instead, it serves to neutralize the cell’s built-in anti- tumor progression—that resulting in colon carcinoma
(Vogelstein and Kinzler, 1993). Still, a rigorous proof ofcancer defenses.
Still, one aspect of this scheme makes little sense: the relevance of the in vitro cell transformation models
to tumorigenesis in vivo will require an additional pieceif a cell shuts downs its growth immediately after ras
oncogene activation, how will the opportunity to inacti- of evidence—the demonstration that a ras oncogene
arising spontaneously in a living tissue actually provokesvate its p16 or p53 genes ever arise? This conundrum
is likely solved by a slight revision of the model depicted senescence, or at least a proliferative slowdown.
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Ruley, H.E. (1990). Cancer Cells 2, 258–268.Senescence vs. Apoptosis
Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W.Serrano et al. are not the first to have noted that onco-
(1997). Cell 88, this issue.genes paradoxically induce cells to stop growing. The
Vogelstein, B., and Kinzler, K.W. (1993). Trends Genet. 9, 138–141.seed of the idea has come from observations of Evan
Weinberg, R.A. (1995). Cell 81, 323–330.and his group that the myc oncogene can, under certain
Whitaker, N.J., Bryan, T.M., Bonnefin, P., Chang, A.C., Musgrove,conditions, elicit another type of anti-proliferative re-
E.A., Braithwaite, A.W., and Reddel, R.R. (1995). Oncogene 11,sponse—apoptosis. (Evan et. al., 1992). Others sub-
971–976.sequently showed that the E1A oncogene, which is
myc-like in some of its actions, also induces apoptosis
(Debbas and White, 1993; Lowe and Ruley, 1993). This
apoptosis can be reversed by several means, among
them, the introduction of ras oncogene (Lin et al., 1995).
Now we begin to see the symmetry in the design of
the circuitry that programs the cell’s defense mecha-
nisms. ras and perhaps other similarly acting oncogenes
induce a senescence which E1A can block. E1A induces
an apoptosis which can be blocked by ras; ras appears
also able to block myc-induced apoptosis (McKenna
et al. 1996). Hence, senescence and apoptosis repre-
sent the two alternative responses that cells mount in
response to these two functionally complementary
classes of oncogenes.
Unexplained by this are the precise physiologic and
biochemical mechanisms by which the myc participates
in these collaborations. Ostensibly, myc intervenes in
the cell cycle clock machinery to prevent ras-induced
senescence, but that is not yet shown experimentally.
An important molecular clue is likely provided by the
recent observation that the Myc protein can induce ex-
pression of the Cdc25A phosphatase, an important acti-
vator of G1 CDKs (Galaktionov et al., 1996).
All this brings us a large step closer to realizing one
of the major goals of current cancer research: rationaliz-
ing the complex, multi-step process of tumor progres-
sion in terms of the workings of the molecular machinery
that operates inside cells to regulate their proliferation.
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